

Molecular Biology in Medicinal Chemistry

Edited by Th. Dingermann, D. Steinhilber and G. Folkers



WILEY-VCH Verlag GmbH & Co. KGaA

**Molecular Biology in
Medicinal Chemistry**
*Edited by Th. Dingermann,
D. Steinhilber and
G. Folkers*

Methods and Principles in Medicinal Chemistry

Edited by R. Mannhold, H. Kubinyi,
G. Folkers

Editorial Board

H.-D. Höltje, H. Timmerman, J. Vacca,
H. van de Waterbeemd, T. Wieland

Recently Published Volumes:

G. Molema, D. K. F. Meijer (eds.)

Drug Targeting

Vol. 12

2001, ISBN 3-527-29989-0

D. Smith, D. Walker, H. van de
Waterbeemd

Pharmacokinetics and Metabolism in Drug Design

Vol. 13

2001, ISBN 3-527-30197-6

T. Lengauer (ed.)

Bioinformatics – From Genomes to Drugs

Vol. 14

2001, ISBN 3-527-29988-2

J. K. Seydel, M. Wiese

Drug-Membrane Interactions

Vol. 15

2002, ISBN 3-527-30427-4

O. Zerbe (ed.)

BioNMR in Drug Research

Vol. 16

2002, ISBN 3-527-30465-7

P. Carloni, F. Alber (eds.)

Quantum Medicinal Chemistry

Vol. 17

2003, ISBN 3-527-30456-8

H. van de Waterbeemd, H. Lennernäs,
P. Artursson (eds.)

Drug Bioavailability

Vol. 18

2003, ISBN 3-527-30438-X

H.-J. Böhm, G. Schneider (eds.)

Protein-Ligand Interactions

Vol. 19

2003, ISBN 3-527-30521-1

R. E. Babine, S. S. Abdel-Meguid (eds.)

Protein Crystallography in Drug Discovery

Vol. 20

2003, ISBN 3-527-30678-1

Molecular Biology in Medicinal Chemistry

Edited by Th. Dingermann, D. Steinhilber and G. Folkers



WILEY-VCH Verlag GmbH & Co. KGaA

Series Editors:

Prof. Dr. Raimund Mannhold

Biomedical Research Center
Molecular Drug Research Group
Heinrich-Heine-Universität
Universitätsstraße 1
40225 Düsseldorf
Germany
raimund.mannhold@uni-duesseldorf.de

Prof. Dr. Hugo Kubinyi

BASF AG Ludwigshafen
c/o Donnersbergstraße 9
67256 Weisenheim am Sand
Germany
kubinyi@t-online.de

Prof. Dr. Gerd Folkers

Department of Applied Biosciences
ETH Zürich
Winterthurerstr. 190
8057 Zürich
Switzerland
folkers@pharma.anbi.ethz.ch

Volume Editors:

Prof. Dr. Theodor Dingermann

Institute of Pharmaceutical Biology
Johann Wolfgang Goethe-University
Marie-Curie-Str. 9
60439 Frankfurt
Germany
dingermann@em.uni-frankfurt.de

Prof. Dr. Dieter Steinhilber

Institute of Pharmaceutical Chemistry
Johann Wolfgang Goethe-University
Marie-Curie-Str. 9
60439 Frankfurt
Germany
steinhilber@em.uni-frankfurt.de

Prof. Dr. Gerd Folkers

Department of Applied Biosciences
ETH Zürich
Winterthurerstr. 190
8057 Zürich
Switzerland
folkers@pharma.anbi.ethz.ch

This book was carefully produced. Nevertheless, authors, editors and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No. applied for

British Library Cataloguing-in-Publication
Data: A catalogue record for this book is available from the British Library
Die Deutsche Bibliothek – CIP
Cataloguing-in-Publication-Data: A catalogue record for this publication is available from Die Deutsche Bibliothek

© 2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany.

Printed on acid-free paper

Typesetting: Asco Typesetters, Hong Kong

Printing: betz-druck gmbh, Darmstadt

Bookbinding: Litges & Dopf Buchbinderei GmbH, Heppenheim

ISBN 3-527-30431-2

Contents

Preface *xv*

Foreword *xvii*

Contributors *xix*

Part I Molecular Targets 1

1 Cellular Assays in Drug Discovery 3

Hugo Albrecht, Daniela Brodbeck-Hummel, Michael Hoeber, Beatrice Nickel and Urs Regenass

- 1.1 Introduction 3
 - 1.1.1 Positioning Cellular Assays 3
 - 1.1.2 Impact on Drug Discovery 4
 - 1.1.3 Classification of Cellular Assays 5
 - 1.1.4 Progress in Tools and Technologies for Cellular Compound Profiling 7
- 1.2 Membrane Proteins and Fast Cellular Responses 8
 - 1.2.1 Receptors 8
 - 1.2.1.1 FLIPR Technology for Detection of Intracellular Calcium Release 9
 - 1.2.1.2 Competitive Immunoassay for Detection of Intracellular cAMP 9
 - 1.2.1.3 Enzyme Fragment Complementation (EFC) Technology 12
 - 1.2.2 Membrane Transport Proteins 12
 - 1.2.2.1 Ion Channels 13
 - 1.2.2.2 MDR Proteins 16
- 1.3 Gene and Protein Expression Profiling in High-throughput Formats 17
 - 1.3.1 Reporter Gene Assays in Lead Finding 17
 - 1.3.2 Reporter Gene Assays in Lead Optimization 21
- 1.4 Spatio-temporal Assays and Subpopulation Analysis 24
 - 1.4.1 Phosphorylation Stage-specific Antibodies 25
 - 1.4.2 Target-protein-specific Antibodies 26
 - 1.4.3 Protein–GFP Fusions 27
 - 1.4.4 Fluorescence Resonance Energy Transfer (FRET) 29
 - 1.4.5 GPCR Activation using Bioluminescence Resonance Energy Transfer (BRET) 31

1.4.6	Protein Fragment Complementation Assays (PCA)	31
1.5	Phenotypic Assays	33
1.5.1	Proliferation/Respiration/Toxicity	33
1.5.2	Apoptosis	34
1.5.3	Differentiation	35
1.5.4	Monitoring Cell Metabolism	36
1.5.5	Other Phenotypic Assays	38
	Acknowledgments	39
	References	39

2 Gene Knockout Models 48

Peter Ruth and Matthias Sausbier

2.1	Introduction	48
2.2	Gene Knockout Mice	48
2.2.1	ES Cells	49
2.2.2	Targeting Vector	52
2.2.3	Selection of Recombinant ES Cells	54
2.2.4	Injection of Recombinant ES Cells into Blastocysts and Blastocyst Transfer to Pseudopregnant Recipients	54
2.2.5	Chimeras and F1 and F2 Offspring	56
2.3	Tissue-Specific Gene Expression	59
2.3.1	Ligand-Activated CRE Recombinases	61
2.3.2	The Tetracycline/Doxycycline-Inducible Expression System	63
2.4	Transgenic Mice	65
2.5	Targeted Gene Disruption in <i>Drosophila</i>	67
2.6	Targeted Gene Knockdown in Zebrafish	68
2.7	Targeted <i>Caenorhabditis Elegans</i> Deletion Strains	70
	References	71

3 Reporter Gene Assay Systems for the Investigation of G-protein-coupled Receptors 73

Michaela C. Dinger and Annette G. Beck-Sickinger

3.1	Receptors and Cellular Communication	73
3.1.1	Ion Channel-linked Receptors	73
3.1.2	Enzyme-linked Cell-surface Receptors	74
3.1.3	GPCRs	75
3.2	Affinity and Activity of GPCR Ligands	77
3.3	The Role of Transcription Factors in Gene Expression	78
3.3.1	CREB	79
3.3.2	SRF	79
3.3.3	STAT Proteins	79
3.3.4	c-Jun	80
3.3.5	NF-AT	80
3.4	Reporter Genes	80
3.4.1	CAT	81

3.4.2	β -Gal	81
3.4.3	β -Glucuronidase	82
3.4.4	AP	83
3.4.5	SEAP	83
3.4.6	β -Lactamase	83
3.4.7	Luciferase	84
3.4.8	GFP	85
3.5	Reporter Gene Assay Systems for the Investigation of GPCRs	85
3.5.1	Application of Luciferase as a Reporter Gene	86
3.5.2	Application of other Reporter Genes for the Investigation of GPCRs	88
	References	91

4 From the Human Genome to New Drugs: The Potential of Orphan G-protein-coupled Receptors 95

Remko A. Bakker and Rob Leurs

4.1	Introduction	95
4.2	GPCRs and the Human Genome	97
4.2.1	GPCR Architecture, Signaling and Drug Action	97
4.2.2	Identification of GPCRs	98
4.2.3	GPCRs in the Postgenomic Era: Orphan Receptors	99
4.3	Ligand Hunting	100
4.3.1	Reverse Pharmacology Approaches to oGPCRs	100
4.3.2	<i>In Silico</i> Approaches	101
4.3.3	Tissue Expression	102
4.3.4	Expression of an oGPCR of Interest	103
4.3.5	Screening Approaches	105
4.4	Screening for oGPCR Ligands using Functional Assays	106
4.4.1	GTP γ S-binding Assays	106
4.4.2	Measurements of cAMP	108
4.4.3	Ca ²⁺ Measurements	109
4.4.4	The Cytosensor Microphysiometer	110
4.4.5	Reporter Gene Assays	111
4.4.6	GPCR–G-protein Coupling	111
4.4.7	Ligand-independent GPCR Activity	113
4.4.8	Novel Screening Strategies	114
4.5	Future Prospects	115
	References	117

Part II Synthesis 123

5 Stereoselective Synthesis with the Help of Recombinant Enzymes 125

Nagaraj N. Rao and Andreas Liese

5.1	Stereoselective Synthesis before the Advent of Genetic Engineering	125
5.2	Classical Methods of Strain Improvement for Stereoselective Synthesis	126

5.3	Genetic Engineering and the Advent of Recombinant Enzymes for Stereoselective Synthesis	129
5.4	β -Lactam Antibiotics	132
5.4.1	Penicillins	132
5.4.2	Cephalosporins	134
5.5	Polyketide Antibiotics	137
5.6	Vitamins	140
5.6.1	L-Ascorbic Acid (Vitamin C)	140
5.6.2	Biotin (Vitamin B ₈ , Vitamin H)	142
5.6.3	Riboflavin (Vitamin B ₂)	143
5.6.4	Nicotinamide (Vitamin B ₃ or PP)	143
5.6.5	Vitamin B ₁₂	144
5.6.6	D-Pantothenic Acid (Vitamin B ₅)	144
5.6.7	Vitamin A	145
5.6.8	Vitamin K (Menaquinone)	146
5.7	Steroids	146
5.8	Other Drugs	146
5.8.1	L-Dihydroxyphenyl Alanine (L-DOPA)	146
5.8.2	Crixivan [®]	147
5.8.3	N-Acetyl Neuraminic Acid (NANA)	147
5.8.4	Cholesterol Biosynthesis Inhibitors (HMG-CoA Reductase Inhibitors)	148
5.8.5	Omapatrilat	149
5.8.6	Hydromorphone	149
5.9	Concluding Remarks	150
	References	150

6 Nucleic Acid Drugs 153

Joachim W. Engels and Jörg Parsch

6.1	Introduction	153
6.2	Chemical Synthesis of Oligonucleotides	153
6.3	Chemical Modifications of Oligonucleotides	155
6.3.1	2'-Modifications	156
6.3.2	Alkyl- and Arylphosphonates	157
6.3.3	Phosphorothioates	159
6.3.4	N3'-P5'-phosphoramidates	160
6.3.5	Morpholino Oligonucleotides	160
6.3.6	PNAs	160
6.3.7	Sterically LNAs	161
6.3.8	Oligonucleotide Conjugates	162
6.3.8.1	5'-End Conjugates	162
6.3.8.2	3'-End Conjugates	162
6.4	Mechanism of Action	163
6.4.1	The Antisense Concept	163
6.4.1.1	Steric Blocking	163

6.4.1.2	RNase H Activation	165
6.4.2	The Triplex Concept	165
6.4.3	Ribozymes	167
6.4.3.1	Structure and Reaction Mechanism	168
6.4.3.2	Triplet Specificity	169
6.4.3.3	Stabilization of Ribozymes	170
6.4.3.4	Inhibition of Gene Expression	170
6.4.3.5	Colocalization	171
6.4.4	RNAi	171
6.5	Positioning Identification of Ribozyme Accessible Sites on Target RNA	172
6.6	Delivery	173
6.7	Application	175
6.8	Conclusion	175
	References	176

Part III Analysis 179

7	Recent Trends in Enantioseparation of Chiral Drugs	181
	<i>Bezhan Chankvetadze</i>	
7.1	Introduction	181
7.2	Current Status in the Development and use of Chiral Drugs	181
7.3	The Role of Separation Techniques in Chiral Drug Development, Investigation and Use	183
7.4	Preparation of Enantiomerically Pure Drugs	184
7.4.1	Resolution of Racemates	185
7.4.2	Chiral Pool	186
7.4.3	Catalytic Asymmetric Synthesis	187
7.4.4	Chromatographic Techniques	189
7.4.4.1	SMB	189
7.4.4.2	Other Chromatographic and Electrophoretic Techniques for the Preparation of Enantiomers	193
7.5	Bioanalysis of Chiral Drugs	194
7.5.1	GC	195
7.5.2	HPLC	197
7.5.3	CE	198
7.5.4	CEC	203
7.6	Future Trends	204
	References	205
8	Affinity Chromatography	211
	<i>Gerhard K. E. Scriba</i>	
8.1	Introduction	211
8.2	Principles of Affinity Chromatography	212
8.3	The Ligand	214

8.3.1	Monospecific Ligands	215
8.3.2	Group-specific Ligands	215
8.3.3	Ligand Development	217
8.4	The Affinity Matrix	218
8.4.1	The Support Material	218
8.4.2	Immobilization of the Ligand	219
8.5	Principles of Operation	222
8.6	Modes of Affinity Chromatography	223
8.6.1	Bioaffinity Chromatography	223
8.6.2	Immunoaffinity Chromatography	224
8.6.3	Dye-ligand-affinity Chromatography	225
8.6.4	Immobilized Metal Ion-affinity Chromatography (IMAC)	225
8.6.5	Hydrophobic Interaction Chromatography (HIC)	226
8.6.6	Covalent Chromatography	228
8.6.7	Membrane Affinity Chromatography	229
8.7	Applications of Affinity Interactions	229
8.7.1	Purification of Pharmaceutical Proteins	230
8.7.1.1	Plasma Proteins	231
8.7.1.2	Recombinant Proteins	231
8.7.2	Analytical Applications	233
8.7.2.1	HPAC	234
8.7.2.2	Affinity Capillary Electrophoresis	236
8.7.2.3	Affinity Biosensors	237
	References	239

9 Nuclear Magnetic Resonance-based Drug Discovery 242

Ulrich L. Günther, Christina Fischer and Heinz Rüterjans

9.1	Introduction	242
9.2	SAR by NMR	243
9.2.1	Sample Preparation	247
9.2.2	Quantitative Evaluation	247
9.2.2.1	Binding Affinities	247
9.2.2.2	Structure Determination from Chemical Shift Perturbations	250
9.2.3	Advanced Technologies in SAR by NMR	250
9.2.4	Data Evaluation	251
9.3	Monitoring Small Molecules	252
9.3.1	Relaxation Methods	253
9.3.2	Diffusion Methods	254
9.3.3	Methods Involving Magnetization Transfer	256
9.3.3.1	Transferred NOE (TrNOE)	256
9.3.3.2	Saturation Transfer	257
9.3.3.3	NOE Pumping	260
9.3.3.4	WaterLOGSY and ePHOGSY	261
9.3.4	Sample Preparation	262

9.4	Conclusions	264
	Acknowledgments	264
	References	265
10	¹³C- and ¹⁵N-Isotopic Labeling of Proteins	269
	<i>Christian Klammt, Frank Bernhard and Heinz Rüterjans</i>	
10.1	Introduction	269
10.2	Expression Systems for the <i>In Vivo</i> Incorporation of ¹³ C and ¹⁵ N Labels into Proteins	270
10.2.1	Protein Production and ¹³ C and ¹⁵ N-labeling in <i>E. coli</i> Expression Systems	271
10.2.2	¹³ C- and ¹⁵ N-labeling of Proteins in <i>P. pastoris</i>	274
10.2.3	¹³ C- and ¹⁵ N-labeling of Proteins by Expression in Chinese Hamster Ovary (CHO) Cells	276
10.2.4	¹³ C- and ¹⁵ N-labeling of Proteins in Other Organisms	276
10.2.5	Strategies for the Production of Selectively ¹³ C- and ¹⁵ N-labeled Proteins	277
10.2.5.1	Selective Labeling of Amino Acids	277
10.2.5.2	Specific Isotope Labeling with ¹³ C	278
10.2.5.3	Segmental Isotope Labeling	279
10.3	Cell-free Isotope Labeling	280
10.3.1	Components of Cell-free Expression Systems	281
10.3.2	Cell-free Expression Techniques	285
10.3.3	Specific Applications of the Cell-free Labeling Technique	289
	References	292
11	Application of Antibody Fragments as Crystallization Enhancers	300
	<i>Carola Hunte and Cornelia Münke</i>	
11.1	Introduction	300
11.2	Crystallization of Membrane Proteins Mediated by Antibody Fragments	303
11.2.1	Overview	303
11.2.2	Generation of Antibodies Suitable for Co-crystallization	306
11.2.2.1	Immunization	306
11.2.2.2	Selection of Antibodies	307
11.2.2.3	Antibody Fragments	308
11.2.3	Protein Purification and Crystallization	314
11.2.3.1	Indirect Immunoaffinity Purification	314
11.2.3.2	Crystallization	316
11.2.3.3	Alternative Approaches for Expansion of the Polar Surface	317
11.3	Conclusions	317
	Acknowledgments	318
	References	318

Part IV Kinetics, Metabolism and Toxicology 323

12 Pharmacogenetics: The Effect of Inherited Genetic Variation on Drug Disposition and Drug Response 325

Kurt Kessler

- 12.1 General 325
- 12.2 Relationships between Genotype and Phenotype 326
- 12.3 Establishing Relations between Genotype and Phenotype 327
- 12.4 Phenotyping versus Genotyping – Prediction of Individual Drug Response 329
- 12.5 Genetic Polymorphism in DMEs 330
- 12.6 Polymorphism of CYP2D6 332
- 12.7 Genetic Polymorphism in Drug Transporters 338
- 12.8 Multidrug Resistance Gene – Marker versus Functional Polymorphism 338
- 12.9 Genetic Polymorphisms in Drug Targets 339
- 12.9.1 Cholesterol Ester Transfer Protein (CETP) Polymorphism as a Biomarker for Response to Lipid-lowering Therapy 340
- 12.9.2 β_2 -Adrenergic Receptor: Predictability of Haplotype versus Single SNPs 340
- 12.9.3 Polygenic Drug Target Polymorphism: Response to Clozapine Treatment 341
- 12.10 Concluding Remarks 341
- References 344

13 Pharmacogenomics of Bioavailability and Elimination 363

Ingolf Cascorbi and Heyo K. Kroemer

- 13.1 Introduction 363
- 13.2 Contribution of Metabolism to Drug Clearance 363
- 13.2.1 CYPs 363
- 13.2.1.1 CYP2C9 365
- 13.2.1.2 CYP2C19 366
- 13.2.1.3 CYP2D6 366
- 13.2.1.4 CYP3A 369
- 13.2.2 Phase II Enzymes 369
- 13.2.2.1 Arylamine *N*-acetyltransferases (NAT2) 369
- 13.2.2.2 Thiopurine-*S*-methyltransferase (TPMT) 370
- 13.3 Drug Transporters: P-glycoprotein (P-gp) 371
- 13.4 Conclusion 373
- References 373

14 Toxicogenomics: Integration of New Molecular Biological Tools in Toxicology 381

Wilbert H. M. Heijne, Ben van Ommen and Rob H. Stierum

- 14.1 Developments in Toxicology 381

14.2	Functional Genomics: New Molecular Biological Tools	383
14.2.1	Genomics	383
14.2.2	Transcriptomics	383
14.2.3	Proteomics	384
14.2.4	Metabolomics	386
14.2.5	Data Processing and Bioinformatics	389
14.2.6	Biological Interpretation	390
14.3	Integration of Functional Genomics Technologies in Toxicology	392
14.3.1	Mechanism Elucidation	392
14.3.2	Transcriptomics Fingerprinting and Prediction of Toxicity	393
14.3.3	Identification of Early Markers of Toxicity	393
14.3.4	Interspecies Extrapolation	394
14.3.5	Extrapolation from <i>In Vitro</i> Experiments to the <i>In Vivo</i> Situation	394
14.3.6	Reduction of Use of Laboratory Animals	394
14.3.7	Combinatorial Toxicology	394
14.4	Illustration: The Application of Toxicogenomics to Study the Mechanism of Bromobenzene-induced Hepatotoxicity	395
14.5	Conclusion	397
	References	397
	Index	399

Preface

Why address molecular biology and related technologies in a series named “Methods and Principles in Medicinal Chemistry”? It was the advent of the silicon chip and the detection of DNA processing enzymes that jointly started an evolutionary track in the 1970s which boosted the whole variety of methodologies in what is today known as the life sciences. Also, the classical field of medicinal chemistry has been augmented and today comprises a huge range of techniques and methodologies from QSAR and structure-based design to the recently developed “high-throughput” synthesis and screening. A paradigmatic change in the 1990s gave rise to a focus on the molecular level of drug action and hence demanded the development of appropriate biological assay technology. This is the point where the present book starts.

In the first part, molecular targets are dealt with, going deep into cellular assay technologies. Cell-based assays imply not only the “simple” detection of one cellular product, but the tracking of a variety of metabolic processes, finally resulting in a multidimensional phenotypic characterization of cellular behavior. In a hierarchical step, the second chapter introduces the “gene knock-out” models, a technique that allows to “design” a disease model within a complex organism to generate a more relevant analytical tool for medicinal chemistry. The subsequent chapter deals with a fascinating readout technology for molecular assays, the so-called reporter genes.

The recent elucidation of the human genome has provided another boost to the whole field. Suddenly, a huge amount of targets was available for study. The question, however, which still remained was: What does the target do within the cellular biochemistry and how is it controlled? Those are the questions tackled in chapter 4, which deals with orphan receptors of the GPCR type and shows the challenges and the opportunities for finding new ligands with hitherto unknown biological activity.

The second part of the book is devoted to synthesis. Two important fields can benefit tremendously from molecular biology and its techniques: Stereoselective synthesis of natural compounds and of their mimics, and synthesis of DNA-derived drugs or protein drugs. The first chapter within this section gives a comprehensive overview about the use of enzymes in stereoselective synthesis, emphasizing recombinant technologies, which greatly enhance the selection of

working tools. The fascinating field of nucleic acid drugs, the design and synthesis, their mimics and their mechanisms of action are the topics of chapter 6.

The third part deals with questions of analysis. Invaluable contributions have come from use of proteins for enantioseparation and affinity chromatography. The use of NMR and associated techniques for structure elucidation is another analytical topic to read about in this section.

Kinetics, metabolism, toxicology, and the very rapidly growing fields of pharmacogenomics and toxicogenomics form the contents of the final part of this book which is unique in its presentation of today's entanglement of the biosciences with medicinal chemistry.

The editors are indebted to the volume editors and the authors, whose work and motivation adds an highly important and fascinating facet to the series and gratefully acknowledge the ongoing support from Frank Weinreich, Wiley-VCH, during the whole project.

September 2003

Raimund Mannhold, Düsseldorf
Hugo Kubinyi, Weisenheim am Sand
Gerd Folkers, Zürich

Foreword

Where to start and where to end was the initial question when we selected the subjects which should be included into a volume dealing with the application of molecular biology in medicinal chemistry. The enormous progress in molecular biology during the last decades has led to the development of many methods with impact on drug discovery and drug development as well.

Modern target identification and validation on the one hand, and drug development and characterization on the other hand require an overlapping spectrum of methods and assays which goes far beyond the classical methodological repertoire of medicinal chemistry. The detailed molecular characterization of interactions of drugs with their targets is as important and demanding as detailed knowledge on drug interactions with the entire physiological system. Concepts and assays are available that provide us with information on drug transport, metabolism and stability. But we also can determine and predict how a system will react upon the application of a drug, even if this drug is considered to act very specifically at a certain target. Methods and concepts of modern pharmacogenomics and toxicogenomics have clearly demonstrated this.

Considering all this we finally decided to organize this volume in four parts: (I) Molecular Targets, (II) Synthesis, (III) Analysis and finally (IV) Kinetics, Metabolism and Toxicology.

The first chapter in part I sets the biological stage by providing an up-to-date description of available “Cellular Assays” and their use and impact on “Drug Discovery”. Assays for membrane proteins and fast cellular responses, assays for gene and protein expression profiling in high-throughput formats, spatio-temporal assays and subpopulation analysis as well as phenotypic assays are introduced.

More complex systems are addressed in the second chapter of part I, which deals with gene knockout mice and techniques available for the generation of such animals.

G-protein coupled receptors are addressed in the third and fourth chapter. In the first of these two chapters, the focus lies on the characterization of G-protein coupled receptors and the application of reporter genes as read out systems, while the subsequent chapter, as a reference to the postgenomic era, discusses strategies for the identification of ligands for orphan G-protein coupled receptors.

Part II of the volume covers several aspects of drug synthesis. A classical overlap

between organic synthesis and biotechnology is the stereoselective synthesis of drugs with the help of recombinant enzymes. The first chapter in this part gives an overview on this topic and provides many examples, underscoring the impact of such strategies.

Nucleic acid drugs eventually will come of age. Their attractiveness as potentially very specific ligands was always in conflict with numerous pharmacokinetic problems. However, various concepts for stabilizing these molecules, the fascinating potential of RNAi and the first approved drugs were strong reminders of these molecules, e.g. as manipulators of cellular signaling. The chapter by Engels and Parsch touches many aspects, including synthesis and application of this type of compounds, including the RNAi technology.

Part III of the book focuses on analytical aspects. Enantioseparation of chiral drugs and affinity chromatography are extremely important tools in drug development and comprehensive reviews on these topics are presented in chapters 7 and 8.

Analytical methods related to structural biology are included in a series of three articles. Two of these papers deal with NMR technologies that have strongly developed during the last decades. This led to the establishment of NMR as an relevant tool for the determination also of macromolecular structures and for the detection and characterization of ligand-target interactions. Chapters 9 and 10 summarize the application of NMR in drug discovery and describe techniques for ^{13}C - and ^{15}N -isotopic labeling of proteins.

Rational drug design depends on exact structure knowledge, which is still best provided by X-ray crystallography. Despite of extreme methodological improvements in this field, structures of membrane receptors, which represent the most important drug targets, are not available. A strong move towards solving this problem might be the use of antibody fragments as crystallization enhancers. Details of this exciting new technique are described in the final chapter of part III.

Pharmacogenomics and toxicogenomics are new fields with considerable impact on future drug development. The last section of the book covers these hot topics, which will eventually initiate the change from the “one size fits all” concept to the “right drug, right size, right person” concept.

The editors would like to gratefully acknowledge the contributions of all authors. They also thank Dr. Frank Weinreich and Wiley-VCH for a steady support during the ongoing project.

September 2003

Theo Dingermann, Frankfurt
Dieter Steinhilber, Frankfurt
Gerd Folkers, Zürich

Contributors

Dr. Hugo Albrecht

Discovery Partners Interational AG
Gewerbestrasse 16
4123 Allschwil
Switzerland

Dr. Remko A. Bakker

Leiden/Amsterdam Center for Drug Research
Department of Medicinal Chemistry
Vrije Universiteit Amsterdam
De Boelelaan 1083
1081 HV Amsterdam
The Netherlands

Prof. Dr. Annette G. Beck-Sickinger

Institute of Biochemistry
University of Leipzig
Talstrasse 33
04103 Leipzig
Germany

Dr. Frank Bernhard

Institute of Biophysical Chemistry
Johann Wolfgang Goethe-University
Marie-Curie-Strasse 9
60439 Frankfurt
Germany

Dr. Daniela Brodbeck-Hummel

Discovery Partners Interational AG
Gewerbestrasse 16
4123 Allschwil
Switzerland

Prof. Dr. Ingolf Cascorbi

Institute of Pharmacology
Ernst-Moritz-Arndt-University Greifswald
Friedrich-Loeffler-Strasse 23D
17487 Greifswald
Germany

Prof. Dr. Bezhan Chankvetadze

Institute of Pharmaceutical and Medicinal
Chemistry
University of Münster
Hittorfstrasse 58–62
48149 Münster
Germany

Dr. Michaela C. Dinger

Institute of Biochemistry
University of Leipzig
Talstrasse 33
04103 Leipzig
Germany

Prof. Dr. Theo Dingermann

Institute of Pharmaceutical Biology
Johann Wolfgang Goethe-University
Marie-Curie-Strasse 9
60439 Frankfurt
Germany

Prof. Dr. Joachim Engels

Institut of Organic Chemistry and Chemical
Biology
Johann Wolfgang Goethe-University
Marie-Curie-Strasse 11
60439 Frankfurt
Germany

Dr. Christina Fischer

Institute of Biophysical Chemistry
Johann Wolfgang Goethe-University
Marie-Curie-Str. 9
60439 Frankfurt
Germany

Prof. Dr. Gerd Folkers

Institute of Pharmaceutical Sciences
ETH Zürich
Wintherthurerstrasse 190

8057 Zürich
Switzerland

Dr. Ulrich L. Günther

Institute of Biophysical Chemistry
Johann Wolfgang Goethe-University
Marie-Curie-Str. 9
60439 Frankfurt
Germany

Dr. Wilbert H. M. Heijne

TNO Food and Nutrition Research
Department of Explanatory Toxicology
Utrechtseweg 48
P.O. Box 360
3600 AJ Zeist
The Netherlands

Dr. Michael Hoever

Discovery Partners International AG
Gewerbstrasse 16
4123 Allschwil
Switzerland

Dr. Carola Hunte

Max-Planck-Institute of Biophysics
Department of Molecular Membrane Biology
Marie-Curie-Strasse 13–15
60439 Frankfurt
Germany

Dr. Kurt Kessler

Industriepark Höchst
Building H 823
65926 Frankfurt am Main
Germany

Dr. Christian Klammt

Institute of Biophysical Chemistry
Johann Wolfgang Goethe-University
Marie-Curie-Strasse 9
60439 Frankfurt
Germany

Prof. Dr. Heyo K. Kroemer

Institute of Pharmacology
Ernst-Moritz-Arndt-University Greifswald
Friedrich-Loeffler-Strasse 23D
17487 Greifswald
Germany

Prof. Dr. Rob Leurs

Leiden/Amsterdam Center for Drug Research
Department of Medicinal Chemistry
Vrije Universiteit Amsterdam
De Boelelaan 1083
1081 HV Amsterdam
The Netherlands

Dr. Andreas Liese

Institute of Biotechnology 2
Research Center Jülich GmbH
P.O. Box 1913
52425 Jülich
Germany

Dr. Cornelia Münke

Max-Planck-Institute of Biophysics
Department of Molecular Membrane Biology
Marie-Curie-Strasse 13–15
60439 Frankfurt
Germany

Dr. Beatrice Nickel

Discovery Partners International AG
Gewerbstrasse 16
4123 Allschwil
Switzerland

Dr. Ben van Ommen

TNO Food and Nutrition Research
Department of Explanatory Toxicology
Utrechtseweg 48
P.O. Box 360
3600 AJ Zeist
The Netherlands

Dr. Jörg Parsch

Beilstein Chemiedaten und Software GmbH
Trakener Strasse 7–9
60487 Frankfurt
Germany

Dr. Nagaraj Rao

Rane Rao Reshamia Laboratories Pvt. Ltd.
Plot 80, Sector 23
Turbhe
Navi Mumbai 400705
India

Dr. Urs Regenass

Discovery Partners International AG
Gewerbstrasse 16
4123 Allschwil
Switzerland

Prof. Dr. Heinz Rüterjans

Institute of Biophysical Chemistry
Johann Wolfgang Goethe-University
Marie-Curie-Strasse 9
60439 Frankfurt
Germany

Prof. Dr. Peter Ruth

Institute of Pharmacy
University of Tübingen
Auf der Morgenstelle 8

72076 Tübingen
Germany

Dr. Matthias Sausbier
Institute of Pharmacy
University of Tübingen
Auf der Morgenstelle 8
72076 Tübingen
Germany

Prof. Dr. Gerhard K. E. Scriba
Institute of Pharmacy
Friedrich-Schiller-University Jena
Philosophenweg 14
07743 Jena
Germany

Prof. Dr. Dieter Steinhilber
Institute of Pharmaceutical Chemistry
Johann Wolfgang Goethe-University
Marie-Curie-Strasse 9
60439 Frankfurt
Germany

Dr. Rob H. Stierum
TNO Food and Nutrition Research
Department of Explanatory Toxicology
Utrechtseweg 48
P.O. Box 360
3600 AJ Zeist
The Netherlands

Part I

Molecular Targets

1

Cellular Assays in Drug Discovery

*Hugo Albrecht, Daniela Brodbeck-Hummel, Michael Hoefer,
Beatrice Nickel and Urs Regenass*

1.1

Introduction

1.1.1

Positioning Cellular Assays

Cell-based assays allow to study the function of pharmaceutical or disease targets within complex environments and in the overall biological context. The application of techniques in molecular biology together with the introduction of new tools and analytical devices has moved readouts of cellular assays from phenotypic endpoints such as cell proliferation, cell death, respiration and functional differentiation to the cellular analysis of functional states of specific signaling molecules and metabolic components.

This transition of cellular assays from “black box” systems to specific target-associated, mechanistic measurements allows the identification of chemical compounds with target-specific or closely associated modulatory function. It can therefore be assumed that cellular assays will play an increasingly important role in early drug discovery, in particular in discovering compounds for target validation (“chemical genetics”; [1] for review) and in hit-to-lead selection as well as in lead optimization. In contrast to biochemical testing of chemicals for modulatory activity on molecular targets, cellular systems can deliver additional information with respect to drug transport, metabolism and stability. Most importantly, pharmacological targets remain in their natural environment when probed for modulation and data should therefore have a higher predictive value (Fig. 1.1).

However, it remains to be said that, in order to use cellular assays in high throughput, cells need to be taken out of their natural habitat and put into culture. This will inevitably lead to alterations in the repertoire of gene and protein expression, and therefore in their phenotype. Cells used in assays should therefore be characterized with respect to the functionality of their intracellular networks, responses to external stimuli, at least for the signaling pathway of interest, and compared with responses and signaling events at the tissue or organ level. In many cases this is unfortunately not yet fully possible.




Fig. 1.1 Chemistry-driven target selection. The increased number of potential pharmaceutical targets emerging from the functional annotation of the human genome requires an efficient process to select those that are valid for modulating disease-relevant pathways and phenotypes. Cellular assays which are tightly coupled in the readout with the target of interest allow us to qualify the hits identified in

cellular or biochemical high-throughput assays with respect to functionality in a physiologically relevant environment. Cellular assays which are not tightly coupled to the target will indicate system effects of compounds and can be interpreted as a cellular “safety” classification. Cellular assays can be used for target and compound prioritization.

1.1.2

Impact on Drug Discovery

Many compounds are lost during the discovery and development process due to undesirable effects or toxicity and lack of required efficacy. A large part of these effects can be related to interactions of the potential drug with targets other than the one initially selected to modulate disease. Cellular test systems have the potential to elucidate the multiplicity of interactions of drugs, and therefore contribute to a better understanding of drug action and drug selection.

The cell is organized in metabolic and signal transduction cascades. Most of these cascades are complex and nonlinear [2]. In addition, different cascades communicate with each other, and form intracellular circuits and domains. Most diseases cannot be explained by one altered step in a pathway, but are due to several alterations that affect networks in a complex way [3, 4]. Similarly, drugs, whether they interact specifically with one single target or with several molecules, will disturb signaling and metabolic cascades in a complex fashion. In addition, since

many cell types make use of the same types of signaling molecules, in a different context, many cell types might be affected to different extents by the same drug. The recent introduction of high-content screening, high-throughput gene and protein expression, as well as metabolite analysis [5, 6], offers the possibility to study system interactions in a multiparallel fashion, and allows a better understanding of the degree and location of interference. Cell-based assays therefore provide a solution to study the modulation of a pharmaceutical target within its complex natural network as well as to assess potential effects on other networks.

Human diseases are characterized by one or several alterations in metabolic and signaling pathways important to maintain cellular homeostasis and the differentiated functions. Cellular assays can offer a representation of such alterations and therefore become relevant functional models to assess drug action.

Nowadays, cellular assays offer the opportunity to identify the intervention points that lead to phenotypic or endpoint alterations. Often, multiple intervention sites are necessary to alter the outcome of biological networks. Similar rules might apply for the number of drug targets that need to be modulated; in particular, for complex diseases. The right targets and drug combinations can be selected only in the case where each single component of a particular pathway can be individually studied, and this is only rendered possible by the use of cellular systems.

The combination of compound that lead to the desired endpoint can be identified by analyzing multiple parameters. The analysis can, moreover, facilitate the assessment of the effect of individual compounds on multiple pathways. This can be taken as a measure for “unwanted effects” (safety profile), but can also lead to the identification of applications in new indications. The analysis of targeted and focused chemical libraries in cellular systems may allow a rapid selection of compounds with various and desired profiles.

Hierarchical, spatio-temporal readouts will generate system-level insight into mechanisms of drug action (intracellular pharmacology) and allow us to predict systemic effects (Fig. 1.2). The development and application of computational tools as well as models of intracellular pathways are a prerequisite to secure data evaluation and interpretation [7, 8]. System-level understanding is only possible by seeking experimental results at the cellular level or beyond.

The recent developments of cellular high-throughput systems, which allow specific measurements of molecular events, render applications in primary screening, and in hit-to-lead selection and lead optimization, in particular, possible. This will enable the development of structure–activity relationships at the system level as a new paradigm in compound selection and decision-making.

1.1.3

Classification of Cellular Assays

Cellular assays have the advantage that the pharmacological targets do not need to be purified. However, in many instances, cellular assays require cell manipulation to allow for a specific signal readout. Overexpression of cell-surface receptors or intracellular proteins can have a substantial effect on the cell physiology and




Fig. 1.2 Schematic cellular circuit and cell systems analysis concept. Cells connect to their environment with a wealth of receptors, channels and transporters. Intracellular signaling and metabolic pathways and networks react to intra- and extracellular stimuli in a spatio-temporal manner. Different cell types can react differently to the same stimuli. It can be envisaged that different cell types, cells from normal or pathological tissue,

or genetically manipulated cells, can be exposed to different stimuli with and without drugs and the cellular reaction can be assessed by sensor systems in a spatio-temporal fashion, from fast responses to phenotypic changes. Multiparametric analysis will identify compounds with target-specific, target-unrelated, reversible or irreversible effects on cellular homeostasis.

have to be taken into account when using the systems for the discovery of novel drugs.

Early reactions to hormones, growth factors and neurotransmitters are often mediated via second-messenger systems or rapid influx and efflux of ions. Post-translational protein modifications and translocation of proteins are the next steps that alter the physiological state of cells. Such changes are able to lead to flow changes in metabolic pathways, and to alterations in gene and protein expression, ultimately leading to new cellular phenotypes, including cell proliferation and cell death.

Cellular assays can be classified by the temporal events occurring when a cell is exposed to alterations in the extra- and intracellular environment (Tab. 1.1). Fast responses indicated by changes in ion or second-messenger concentrations ultimately lead to functional and phenotypic changes.

Some of the cellular events can be recapitulated in so-called model systems, which might be easier to handle and to manipulate genetically than mammalian cells. Yeast has turned out to be an organism of choice, where metabolic signals and protein-protein interactions relevant for signal transduction can be translated